Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma.

Zaidi AH, Gopalakrishnan V, Kasi PM, Zeng X, Malhotra U, Balasubramanian J, Visweswaran S, Sun M, Flint MS, Davison JM, Hood BL, Conrads TP, Bergman JJ, Bigbee WL, Jobe BA.

Cancer. 2014 Dec 15;120(24):3902-13. doi: 10.1002/cncr.28963. Epub 2014 Aug 5.

2.

Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma.

Shah AK, Cao KA, Choi E, Chen D, Gautier B, Nancarrow D, Whiteman DC, Saunders NA, Barbour AP, Joshi V, Hill MM.

Mol Cell Proteomics. 2015 Nov;14(11):3023-39. doi: 10.1074/mcp.M115.050922. Epub 2015 Sep 24.

3.

Esophageal cancer metabolite biomarkers detected by LC-MS and NMR methods.

Zhang J, Bowers J, Liu L, Wei S, Gowda GA, Hammoud Z, Raftery D.

PLoS One. 2012;7(1):e30181. doi: 10.1371/journal.pone.0030181. Epub 2012 Jan 23.

4.

Squamous Cellular Carcinoma Antigen Serum Determination as a Biomarker of Barrett Esophagus and Esophageal Cancer: A Phase III Study.

Maddalo G, Fassan M, Cardin R, Piciocchi M, Marafatto F, Rugge M, Zaninotto G, Pozzan C, Castoro C, Ruol A, Biasiolo A, Farinati F.

J Clin Gastroenterol. 2018 May/Jun;52(5):401-406. doi: 10.1097/MCG.0000000000000790.

PMID:
28422774
5.

DCLK1 is detectable in plasma of patients with Barrett's esophagus and esophageal adenocarcinoma.

Whorton J, Sureban SM, May R, Qu D, Lightfoot SA, Madhoun M, Johnson M, Tierney WM, Maple JT, Vega KJ, Houchen CW.

Dig Dis Sci. 2015 Feb;60(2):509-13. doi: 10.1007/s10620-014-3347-4. Epub 2014 Oct 5.

PMID:
25283374
6.

Goblet Cell Ratio in Combination with Differentiation and Stem Cell Markers in Barrett Esophagus Allow Distinction of Patients with and without Esophageal Adenocarcinoma.

Schellnegger R, Quante A, Rospleszcz S, Schernhammer M, Höhl B, Tobiasch M, Pastula A, Brandtner A, Abrams JA, Strauch K, Schmid RM, Vieth M, Wang TC, Quante M.

Cancer Prev Res (Phila). 2017 Jan;10(1):55-66. doi: 10.1158/1940-6207.CAPR-16-0117. Epub 2016 Nov 2.

7.

Profiling of circulating microRNAs in patients with Barrett's esophagus and esophageal adenocarcinoma.

Bus P, Kestens C, Ten Kate FJ, Peters W, Drenth JP, Roodhart JM, Siersema PD, van Baal JW.

J Gastroenterol. 2016 Jun;51(6):560-70. doi: 10.1007/s00535-015-1133-5. Epub 2015 Nov 19.

8.

Lung cancer serum biomarker discovery using label-free liquid chromatography-tandem mass spectrometry.

Zeng X, Hood BL, Zhao T, Conrads TP, Sun M, Gopalakrishnan V, Grover H, Day RS, Weissfeld JL, Wilson DO, Siegfried JM, Bigbee WL.

J Thorac Oncol. 2011 Apr;6(4):725-34. doi: 10.1097/JTO.0b013e31820c312e.

9.

Epigenetic biomarkers in esophageal cancer.

Kaz AM, Grady WM.

Cancer Lett. 2014 Jan 28;342(2):193-9. doi: 10.1016/j.canlet.2012.02.036. Epub 2012 Mar 7. Review.

10.

Circulating Serum Exosomal miRNAs As Potential Biomarkers for Esophageal Adenocarcinoma.

Chiam K, Wang T, Watson DI, Mayne GC, Irvine TS, Bright T, Smith L, White IA, Bowen JM, Keefe D, Thompson SK, Jones ME, Hussey DJ.

J Gastrointest Surg. 2015 Jul;19(7):1208-15. doi: 10.1007/s11605-015-2829-9. Epub 2015 May 6.

PMID:
25943911
11.

Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma.

Rizk NP, Servais EL, Tang LH, Sima CS, Gerdes H, Fleisher M, Rusch VW, Adusumilli PS.

Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):482-6. doi: 10.1158/1055-9965.EPI-11-0993. Epub 2012 Jan 11.

12.

Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus.

Shah AK, Hartel G, Brown I, Winterford C, Na R, Cao KL, Spicer BA, Dunstone MA, Phillips WA, Lord RV, Barbour AP, Watson DI, Joshi V, Whiteman DC, Hill MM.

Mol Cell Proteomics. 2018 Dec;17(12):2324-2334. doi: 10.1074/mcp.RA118.000734. Epub 2018 Aug 10.

PMID:
30097534
13.

Diagnostic correlation between the expression of the DNA repair enzyme N-methylpurine DNA glycosylase and esophageal adenocarcinoma onset: a retrospective pilot study.

Zaïr ZM, Johnson GE, Griffiths AP, Jenkins GJ.

Dis Esophagus. 2013 Aug;26(6):644-50. doi: 10.1111/dote.12003. Epub 2012 Nov 8.

PMID:
23137018
14.

MicroRNA Expression Signatures During Malignant Progression From Barrett's Esophagus.

Bansal A, Gupta V, Wang K.

J Cell Biochem. 2016 Jun;117(6):1288-95. doi: 10.1002/jcb.25497. Epub 2016 Feb 16.

PMID:
26808728
15.

Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets.

Mechref Y, Hussein A, Bekesova S, Pungpapong V, Zhang M, Dobrolecki LE, Hickey RJ, Hammoud ZT, Novotny MV.

J Proteome Res. 2009 Jun;8(6):2656-66. doi: 10.1021/pr8008385.

16.

D-mannose: a novel prognostic biomarker for patients with esophageal adenocarcinoma.

Gu J, Liang D, Pierzynski JA, Zheng L, Ye Y, Zhang J, Ajani JA, Wu X.

Carcinogenesis. 2017 Feb 1;38(2):162-167. doi: 10.1093/carcin/bgw207.

PMID:
28062409
17.

Predictive value of MicroRNAs in the progression of barrett esophagus to adenocarcinoma in a long-term follow-up study.

Revilla-Nuin B, Parrilla P, Lozano JJ, de Haro LF, Ortiz A, Martínez C, Munitiz V, de Angulo DR, Bermejo J, Molina J, Cayuela ML, Yélamos J.

Ann Surg. 2013 May;257(5):886-93. doi: 10.1097/SLA.0b013e31826ddba6.

PMID:
23059500
18.

A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome.

Lanuti M, Liu G, Goodwin JM, Zhai R, Fuchs BC, Asomaning K, Su L, Nishioka NS, Tanabe KK, Christiani DC.

Clin Cancer Res. 2008 May 15;14(10):3216-22. doi: 10.1158/1078-0432.CCR-07-4932.

19.

MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.

Maru DM, Singh RR, Hannah C, Albarracin CT, Li YX, Abraham R, Romans AM, Yao H, Luthra MG, Anandasabapathy S, Swisher SG, Hofstetter WL, Rashid A, Luthra R.

Am J Pathol. 2009 May;174(5):1940-8. doi: 10.2353/ajpath.2009.080718. Epub 2009 Mar 26.

20.

Increasing diagnostic accuracy to grade dysplasia in Barrett's esophagus using an immunohistochemical panel for CDX2, p120ctn, c-Myc and Jagged1.

Karamchandani DM, Lehman HL, Ohanessian SE, Massé J, Welsh PA, Odze RD, Goldblum JR, Berg AS, Stairs DB.

Diagn Pathol. 2016 Feb 29;11:23. doi: 10.1186/s13000-016-0473-7.

Supplemental Content

Support Center